A new marker for stratification of ILD in dermatomyositis: Anti MDA5 antibodies! Japanese study MDA5 (201-300) positivity associated w/ Lower 6-month progression-free survival (43% vs. 74%) Lower 5-year survival rates (34% vs. 66%) Validation in other populations awaited https://t.co/IBiYyATer4